Australian Biotech Radiopharm Expands Cancer Drug Production with Strategic Partnership

Rhea-AI Filing Summary

Radiopharm Theranostics has filed a Form 6-K to report the signing of a significant supply agreement with Cyclotek for 161Tb-KLK3-mAb, as announced on the Australian Securities Exchange on June 24, 2025.

The filing consists of an announcement made to the Australian Securities Exchange regarding the supply agreement, which has been attached as Exhibit 99.1 to the Form 6-K. The company files annual reports under Form 20-F and is not subject to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

This Form 6-K and its exhibits are not considered "filed" for Securities Exchange Act purposes and will not be automatically incorporated by reference into future securities filings unless specifically referenced. The document was signed by Company Secretary Phillip Hains.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of June 2025

 

Commission File Number: 001-41621

 

RADIOPHARM THERANOSTICS LIMITED

(Name of Registrant)

 

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes ☐       No ☒

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

 

 

 

 

 

 

RADIOPHARM THERANOSTICS LIMITED

 

EXPLANATORY NOTE

 

Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on June 24, 2025 titled:

 

  -   “RAD and Cyclotek Sign Supply Agreement for 161Tb-KLK3-mAb”  

 

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

 

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

1

 

 

EXHIBITS

 

Exhibit Number	 	Description
99.1	 	RAD and Cyclotek Sign Supply Agreement for 161Tb-KLK3-mAb

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 	RADIOPHARM THERANOSTICS LIMITED
 	 	 
Date: June 24, 2025	By:	/s/ Phillip Hains
 	 	Phillip Hains
 	 	Company Secretary

 

3

 

FAQ

What supply agreement did RADX announce in June 2025?

RADX announced a supply agreement with Cyclotek for 161Tb-KLK3-mAb, as disclosed in their Form 6-K filed on June 28, 2025. The agreement was initially announced to the Australian Securities Exchange on June 24, 2025.

When did RADX file their latest Form 6-K?

RADX filed their Form 6-K on June 28, 2025, reporting on a material event that was originally announced to the Australian Securities Exchange on June 24, 2025.

Who signed RADX's Form 6-K filed in June 2025?

The Form 6-K was signed by Phillip Hains, Company Secretary of Radiopharm Theranostics Limited, on June 24, 2025.

What type of annual reports does RADX file with the SEC?

According to the Form 6-K, RADX files annual reports under Form 20-F, as indicated by the checked box in the filing, which is typical for foreign private issuers listed on U.S. exchanges.